<DOC>
	<DOCNO>NCT02885974</DOCNO>
	<brief_summary>The purpose study compare patient tumor tissue treatment chemotherapy plus celecoxib . Investigators look gene expression , see effect celecoxib may tumor cell .</brief_summary>
	<brief_title>Celecoxib With Chemotherapy Localized , Muscle-Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Subjects legally authorize representative must inform investigational nature study , must sign give write informed consent accordance institutional federal guideline . Patients must histologically prove urothelial carcinoma bladder . Those mixed histology , include component urothelial carcinoma , eligible . Pure small cell carcinoma , pure adenocarcinoma , pure squamous cell carcinoma exclude . Patients must Stage cT2T4a N0 M0 disease . Clinical T stage base TURBT sample , exam anesthesia crosssectional imaging study . Patients must undergo cystoscopy TURBT part stag procedure within 56 day prior registration . To exclude nonbulky/lowrisk tumor , subject must document muscle invasion least one following : . Disease measure least 10 mm crosssectional imaging . Bladder thicken imaging , , adequate . ii . The presence tumorassociated hydronephrosis . Patients must stag scan abdominal/pelvic CT MRI scan , CT scan xray chest within 56 day prior registration . If alkaline phosphatase &gt; 1.5 x upper limit normal ( ULN ) , presence suspicious bone pain , clinical suspicion bone metastasis , whole body bone scan require within 56 day prior registration . Patients must Zubrod performance status 0 , 1 2 . Patients must 18 year age old . Patients must adequate renal function evidence calculated creatinine clearance ≥ 50 mL/min . The serum creatinine value use calculation must obtain within 28 day prior registration . Patients must adequate hepatic function ( within 28 day prior registration ) , define : . Total bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) ( ≤ 2.5 x ULN Gilbert 's disease ) ; ii . SGOT ( AST ) ≤ 2 x institutional ULN ; iii . SGPT ( ALT ) ≤ 2 x institutional ULN . Patients must adequate hematologic function ( within 28 day prior registration ) , define : . Absolute neutrophil count ( ANC ) ≥ 1,500/μL ; ii . Hemoglobin ≥ 9 g/dL ; iii . Platelets ≥ 100,000/μL . Patients must tumor tissue transurethral resection bladder tumor ( TURBT ) available submission sufficient IHC testing . Patient must agree submission two TUR formalfixed paraffin embed ( FFPE ) tissue block ; least one block must contain viable tumor least 1 cm3 size . The diagnostic TURBT sample must obtain within 56 day prior registration . Patients must consent submission FFPE block and/or unstained slide . Patients must receive previous systemic cytotoxic chemotherapy urothelial carcinoma . Patients must peripheral neuropathy ≥ Grade 2 . Patients must presence Class III IV heart failure , accord New York Heart Association Classifications , know leave ventricular ejection fraction le 50 % . Note : LVEF evaluation echocardiogram multigated acquisition scan ( MUGA ) require prior registration . Patients must significant history bleed event . Patients history significant bleeding episode ( e.g . hemoptysis , upper low GI bleeding , grade 3 4 gross hematuria unable controlled transurethral resection bladder tumor ) within 6 month registration eligible . No arterial thrombotic event within 6 month registration , include transient ischemic attack ( TIA ) , cerebrovascular accident ( CVA ) , peripheral arterial thrombus , unstable angina angina require surgical medical intervention past 6 month , myocardial infarction ( MI ) . Patients clinically significant peripheral artery disease ( i.e. , claudication le one block ) ineligible . Patients experience deep venous thrombosis pulmonary embolus within past 6 month must stable therapeutic anticoagulation enrol study . Patients must clinically relevant hear impairment &gt; Grade 2 . Patients must aspirin sensitive asthma . Patients must know hypersensitivity cisplatin , gemcitabine , celecoxib . Patients must incidence uncontrolled medical illness ( e.g . active cardiac symptom , active systemic infection , etc . ) would limit patient 's ability participate protocol . Patients must pregnant nursing due potential teratogenic side effect protocol treatment . Women/men reproductive potential must agree use effective contraceptive method 6 month complete protocol treatment . A negative pregnancy test require within 7 day prior registration woman childbearing potential . Patients ineligible plan regular use NSAIDs dose 2 time per week ( average ) aspirin 325 mg least three time per week , average . Lowdose aspirin exceed 100 mg/day permit . Patients agree stop regular NSAIDs high dose aspirin eligible wash period require .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Celecoxib</keyword>
	<keyword>Bladder Cancer</keyword>
</DOC>